Arcadia Biosciences (RKDA) Tops Q2 EPS by 2c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts RKDA Hot Sheet
Join SI Premium – FREE
Arcadia Biosciences (NASDAQ: RKDA) reported Q2 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $991 thousand versus the consensus estimate of $1.3 million.
For earnings history and earnings-related data on Arcadia Biosciences (RKDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- Goldman Sachs Upgrades Technip Energies NV (TE:FP) to Buy
- ICICI Prudential Asset Management (ICICIAMC:IN) PT Lowered to INR3,330 at BofA Securities
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
